Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
28 Julio 2023 - 7:00AM
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a
clinical-stage oncology company developing innovative, full-length
multispecific antibodies (Biclonics® and Triclonics®), today
announced two abstracts were selected for presentation at the
European Society for Medical Oncology Congress (ESMO) 2023.
The presentations will highlight updated interim clinical data
for the targeted bispecific antibody, zenocutuzumab (Zeno), with an
abstract and oral presentation concerning NRG1 fusion positive
(NRG1+) non-small cell lung cancer (NSCLC) and an abstract
presentation concerning NRG1+ pancreatic ductal adenocarcinoma
(PDAC). The abstracts will be presented at the ESMO Congress 2023
taking place in Madrid, Spain October 20-24, 2023.
Merus is currently enrolling patients into the phase 1/2 eNRGy
trial to assess the safety and anti-tumor activity of Zeno
monotherapy in NRG1+ cancer.
Title: Durable efficacy of
zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1
fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)Speaker:
Alison SchramMini Oral 1315MOLecture Time
9:35-9:40 CESTSaturday, October 21
Title: Durable efficacy of
zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1
fusion-positive (NRG1+) pancreatic ductal adenocarcinoma
(PDAC)Poster Session 1618PSunday, October 22
The full abstracts will be published online via
the ESMO website at 00:05 CEST on Monday, October 16. They will be
available concurrently on the Merus website.
About the eNRGy Clinical TrialMerus is
currently enrolling patients in the phase 1/2 eNRGy trial to assess
the safety and anti-tumor activity of Zeno monotherapy in NRG1+
cancer. The eNRGy trial consists of three cohorts: NRG1+
pancreatic cancer; NRG1+ non-small cell lung cancer; and other
NRG1+ cancer. Further details, including current trial sites,
can be found at www.ClinicalTrials.gov and Merus’ trial
website at www.nrg1.com or by calling 1-833-NRG-1234.
About ZenoZeno is an antibody-dependent
cell-mediated cytotoxicity (ADCC)-enhanced Biclonics® that
utilizes the Merus Dock & Block® mechanism to inhibit
the neuregulin/HER3 tumor-signaling pathway in solid tumors with
NRG1 fusions (NRG1+ cancer). Through its unique mechanism of
binding to HER2 and potently blocking the interaction of HER3 with
its ligand NRG1 or NRG1-fusion proteins, Zeno has the potential to
be particularly effective against NRG1+ cancer. In preclinical
studies, Zeno potently inhibits HER2/HER3 heterodimer formation
thereby inhibiting oncogenic signaling pathways, leading to
inhibition of tumor cell proliferation, and blocking tumor cell
survival.
About Merus N.V.Merus is a clinical-stage
oncology company developing innovative full-length human bispecific
and trispecific antibody therapeutics, referred to
as Multiclonics®. Multiclonics® are manufactured
using industry standard processes and have been observed in
preclinical and clinical studies to have several of the same
features of conventional human monoclonal antibodies, such as long
half-life and low immunogenicity. For additional information,
please visit Merus’
website, Twitter and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding the clinical
development of zenocutuzumab, future clinical trial results or
interim data, clinical activity and safety profile of zenocutuzumab
in the on-going eNRGy trial and planned abstracts and presentation.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, the
following: our need for additional funding, which may not be
available and which may require us to restrict our operations or
require us to relinquish rights to our technologies or Biclonics®,
Triclonics® and multispecific antibody candidates; potential delays
in regulatory approval, which would impact our ability to
commercialize our product candidates and affect our ability to
generate revenue; the lengthy and expensive process of clinical
drug development, which has an uncertain outcome; the unpredictable
nature of our early stage development efforts for marketable drugs;
potential delays in enrollment of patients, which could affect the
receipt of necessary regulatory approvals; our reliance on third
parties to conduct our clinical trials and the potential for those
third parties to not perform satisfactorily; impacts of the
COVID-19 pandemic; we may not identify suitable Biclonics® or
bispecific antibody candidates under our collaborations or our
collaborators may fail to perform adequately under our
collaborations; our reliance on third parties to manufacture our
product candidates, which may delay, prevent or impair our
development and commercialization efforts; protection of our
proprietary technology; our patents may be found invalid,
unenforceable, circumvented by competitors and our patent
applications may be found not to comply with the rules and
regulations of patentability; we may fail to prevail in potential
lawsuits for infringement of third-party intellectual property; and
our registered or unregistered trademarks or trade names may be
challenged, infringed, circumvented or declared generic or
determined to be infringing on other marks.
These and other important factors discussed under the caption
“Risk Factors” in our Annual Report on Form 10-Q for the period
ended March 31, 2023, filed with the Securities and
Exchange Commission, or SEC, on May
4, 2023, and our other reports filed with
the SEC, could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change, except as required under applicable law. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Multiclonics®, Biclonics® and Triclonics® are
registered trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
Investor Relations and Corporate Communications
617-230-4165
k.farren@merus.nl
Merus NV (NASDAQ:MRUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Merus NV (NASDAQ:MRUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024